Physician profile
Orvar T Jonsson
NPI 1831302009
$141,874.65
in general payments reported to CMS, 2019-2025
28 companies · $24K in 2025
The $24K reported for 2025 was more than what 86% of Advanced Heart Failure and Transplant Cardiology providers received nationally (typical 2025 total: $1,046).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $48K · 2020: $17K · 2021: $2,299 · 2022: $8,102 · 2023: $23K · 2024: $19K · 2025: $24K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $48K · Food and Beverage: $7,828 · Consulting Fee: $5,163 · Travel and Lodging: $5,159 · Education: $88.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $48,229.25 |
| Food and Beverage | $7,828.17 |
| Consulting Fee | $5,162.50 |
| Travel and Lodging | $5,159.08 |
| Education | $88.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $49,638.90 | 2019-2025 | Opsumit, Uptravi, Opsynvi |
| Novartis Pharmaceuticals Corporation | $48,937.62 | 2019-2024 | |
| Abbott Laboratories | $23,684.03 | 2019-2025 | Cardiomems, Thoratec Heartmate 3 Lvas Implant Kit, Amplatzer Amulet |
| Astrazeneca Pharmaceuticals Lp | $9,611.93 | 2020-2022 | |
| Endotronix, INC. | $4,523.53 | 2022-2025 | Cordella Pulomonary Artery Pressure Sensor |
| Cvrx, INC. | $3,004.64 | 2024-2025 | Barostim Neo System |
| Abiomed | $930.95 | 2023-2025 | Impella |
| Janssen Pharmaceuticals, INC | $304.58 | 2019-2024 | Xarelto |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $257.75 | 2019-2023 | Lifevest |
| E.R. Squibb & Sons, L.L.C. | $232.36 | 2020-2023 | Camzyos, Eliquis |
| United Therapeutics Corporation | $156.59 | 2019-2025 | Tyvaso, Remodulin |
| Heartflow, INC. | $129.96 | 2025 | |
| Zoll Respicardia, INC. | $111.58 | 2019 | |
| Impulse Dynamics (USA) INC. | $65.89 | 2024-2025 | Optimizer |
| Chiesi USA, INC. | $50.39 | 2019-2021 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $41.69 | 2024-2025 | Winrevair |
| Pfizer INC. | $41.51 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $33.19 | 2021-2025 | Jardiance |
| Daiichi Sankyo INC. | $32.87 | 2023 | Injectafer |
| Cardiac Dimensions, INC. | $25.87 | 2025 | |
| Csl Behring | $17.24 | 2022 | |
| Lexicon Pharmaceuticals, INC. | $16.21 | 2023 | Inpefa |
| Astellas Pharma US INC | $13.75 | 2019 | |
| Lundbeck LLC | $11.62 | 2020 |
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Orvar Jonsson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.